Research ArticleClinical Studies

Platinum–Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC

LINDA MICHELSEN and JENS BENN SØRENSEN
Anticancer Research November 2015, 35 (11) 6255-6259;

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Progression-free survival in patients with advanced non-small cell lung cancer who received induction with carboplatin/bevacizumab without (Group A, n=20) and with (Group B, n=22) subsequent pemetrexed switch maintenance. p-Value <0.001.

  • Figure 2.
    Figure 2.

    Overall survival in patients with advanced non-small cell lung cancer who received treatment with carboplatin/vinorelbin/bevacizumab without (Group A, n=20) and with (Group B, n=22) subsequent pemetrexed switch maintenance. p-Value<0.25.

Tables

  • Table I.
  • Table II.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Platinum–Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC
LINDA MICHELSEN, JENS BENN SØRENSEN
Anticancer Research Nov 2015, 35 (11) 6255-6259;
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords